Trial · NCT04611789
A Study of LY3832479 (LY-CoV016) in Healthy Participants 1
NCT04611789, Phase 1, Completed, Eli Lilly and Company; results first posted 2021-12-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of LY3832479 (LY-CoV016) in Healthy Participants 1. Trials, record NCT04611789. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04611789
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of LY3832479 (LY-CoV016) in Healthy Participants 1
- NCT number
- NCT04611789
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 18 participants, actual
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Healthy
- Interventions
- LY3832479, Placebo
- First posted
- 2020-11-02
- Last updated
- 2021-12-06
- Results first posted
- 2021-12-06
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Tlast (AUC[0-tlast]) of LY3832479 | Day 1, 2, 3, 4, 5, 6, 7, 15, 29, 60 and 85 postdose | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time 0 to tlast (AUC\[0-tlast\]) of LY3832479. |
| Primary | PK: Maximum Serum Concentration (Cmax) of LY3832479 | Day 1, 2, 3, 4, 5, 6, 7, 15, 29, 60 and 85 postdose | PK: Maximum Serum Concentration (Cmax) of LY3832479. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Tlast (AUC[0-tlast]) of LY3832479 | Day 1, 2, 3, 4, 5, 6, 7, 15, 29, 60 and 85 postdose | All randomized participants who received study drug and had evaluable PK data. | microgram*day per milliliter (μg*day/mL) | GEOMETRIC_MEAN |
| PRIMARY | PK: Maximum Serum Concentration (Cmax) of LY3832479 | Day 1, 2, 3, 4, 5, 6, 7, 15, 29, 60 and 85 postdose | All randomized participants who received study drug and had evaluable PK data. | μg/mL | GEOMETRIC_MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Tlast (AUC[0-tlast]) of LY3832479 | 350 mg LY3832479 | 1560 | Geometric Coefficient of Variation 80 | microgram*day per milliliter (μg*day/mL) | |
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Tlast (AUC[0-tlast]) of LY3832479 | 1000 mg LY3832479 | 4530 | Geometric Coefficient of Variation 31 | microgram*day per milliliter (μg*day/mL) | |
| PK: Maximum Serum Concentration (Cmax) of LY3832479 | 350 mg LY3832479 | 39.1 | Geometric Coefficient of Variation 39 | μg/mL | |
| PK: Maximum Serum Concentration (Cmax) of LY3832479 | 1000 mg LY3832479 | 91.9 | Geometric Coefficient of Variation 35 | μg/mL |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 4 | |
| Overall Study | STARTED | 350 mg LY3832479 | 7 | |
| Overall Study | STARTED | 1000 mg LY3832479 | 7 | |
| Overall Study | COMPLETED | Placebo | 3 | |
| Overall Study | COMPLETED | 350 mg LY3832479 | 7 | |
| Overall Study | COMPLETED | 1000 mg LY3832479 | 7 | |
| Overall Study | NOT COMPLETED | Placebo | 1 | |
| Overall Study | NOT COMPLETED | 350 mg LY3832479 | 0 | |
| Overall Study | NOT COMPLETED | 1000 mg LY3832479 | 0 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site reaction | General disorders | Placebo SC | 0 | 4 | 0 |
| other | Injection site reaction | General disorders | 350 mg LY3832479 SC | 0 | 7 | 0 |
| other | Injection site reaction | General disorders | 1000 mg LY3832479 SC | 1 | 7 | 4 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo SC | 0 | 4 |
| Total, all-cause mortality | 350 mg LY3832479 SC | 0 | 7 |
| Total, all-cause mortality | 1000 mg LY3832479 SC | 0 | 7 |
| Total, other adverse events | Placebo SC | 0 | 4 |
| Total, other adverse events | 350 mg LY3832479 SC | 0 | 7 |
| Total, other adverse events | 1000 mg LY3832479 SC | 1 | 7 |
| Total, serious adverse events | Placebo SC | 0 | 4 |
| Total, serious adverse events | 350 mg LY3832479 SC | 0 | 7 |
| Total, serious adverse events | 1000 mg LY3832479 SC | 0 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04611789
GET https://conductscience.org/api/trials/v1/NCT04611789/registered